SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending downwards amidst discussions about earnings, where increased costs outpaced revenue growth. Concerns over valuation, the impact of expiring tax credits, and Elon Musk's proposed compensation package are also driving bearish sentiment. Despite this, some bulls remain optimistic, focusing on the potential of AI, energy storage, and robotaxis.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid discussions of the U.S. government potentially taking an equity stake in quantum computing firms, sparking excitement about the industry's future. Community members are debating whether this signals long-term growth potential or a short-term pump, with some highlighting the potential impact of government funding on the sector. The conversations also include mentions of quantum-resistant crypto and comparisons to other quantum computing stocks.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ is trending following news it demonstrated quantum-safe Bitcoin, which the community sees as essential for the future of cryptocurrency. Bullish investors highlight the company's first-mover advantage in quantum security and potential for government and institutional adoption. Some are also drawing comparisons to other quantum computing stocks and noting BTQ's smaller market cap.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the community discusses the potential impact of government funding and equity stakes in quantum computing firms. Some believe this could lead to significant growth, while others view it as a short-term pump or a sign of government overreach. The stock's recent volatility and potential for both bullish and bearish scenarios are also being debated.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid discussions of potential government equity stakes in quantum computing firms, sparking both excitement and skepticism within the investment community. While some view this as a major catalyst for the sector, others question the significance of the reported funding amount and its long-term impact. Community members are actively debating the validity and potential implications of this development for RGTI and its competitors.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as investors discuss the potential impact of the Trump administration considering equity stakes in quantum computing firms, a move that could mirror an "Intel model" for federal funding. Community talking points include speculation on whether the government is becoming a major venture capitalist and if this will drive QUBT higher. Some traders are wary of a potential pump and dump.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is trending amid discussions around potential government investment in quantum computing firms, spurred by a *Wall Street Journal* report. The community is debating whether SEALSQ could benefit and some anticipate a potential short squeeze. Also, upcoming milestones around the release of the Quantum Shield QS7001 chip.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

Beasley Broadcast Group ($BBGI) is trending due to its low float, leading to speculation of a potential short squeeze similar to other recent runners. Community members are discussing the stock's chart setup and anticipating a breakout, with some setting ambitious price targets. However, some are cautioning about the company's financials, citing concerns about debt and revenue.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending due to positive Q3 earnings, exceeding expectations with a jump in adjusted operating profit driven by network growth, which has sparked bullish sentiment. The community is actively discussing call option sweeps and potential for a short squeeze, while also weighing whether the company is a 'serial disappointer' or a 'whole new company'. Broader context includes Nokia's involvement in 5G, AI, and strategic partnerships, suggesting a transformation beyond its traditional telecom role.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending due to technical analysis pointing to bullish momentum and a potential continuation of its upward trend, particularly following reactions from identified "Blue Box" areas. Community discussions revolve around Elliott Wave patterns, with many traders observing buying opportunities after recent pullbacks and a break above the July peak. Some analysts suggest a path towards higher targets before profit-taking, while others note range-bound trading and the need for bulls to overcome resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah Capital, called for the sale of the company, citing persistent underperformance.Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shahcapital.com/shah-capital-calls-for-sale-of-novavax/">said</a> in a letter to the Novavax board of directors that since March 2023, its concerns have accelerated with “Nuvoxovid’s rollout slipups including this fall, timid/ineffective marketing, extremely poor capital market actions, and tremendous lack of accountability.”“Novavax’s IP and scientific capabilities will have far greater upside potential in the hands of large capable pharma entity,” Shah Capital said, while recommending an immediate formal strategic review for the sale of the company.The investor recapped several alleged missteps that have damaged the company, including critical marketing slips resulting in a small 2% Covid vaccine market share in the 2024 season for Novavax’s protein-based Nuvaxovid vaccine.Shah Capital also expressed surprise at Nuvaxovid’s market share, noting that the increasing criticism for mRNA vaccines made by Novavax’s peers should benefit Novavax’s protein-based vaccine.“With more states becoming increasingly averse to mRNA vaccines including Florida, Texas, Minnesota, Idaho, Iowa, Montana, South Carolina, Tennessee &amp; Kentucky; some of which are trying to ban mRNA altogether, we find it inconceivable as to how management has been unsuccessful gaining meaningful share given the tens of millions of senior citizens/high risk/immunocompromised individuals in just those 9 states alone. Sales are miserable for the third consecutive year,” it said.The investor also noted that awareness regarding Nuvaxovid continues to be “alarmingly low.” Shah further alleged that the “execution failure and ineffective leadership” have taken their toll on investor confidence and trust.Last year, Shah Capital waged a proxy campaign against the re-election of some directors on the company board at Novavax’s 2024 Annual Meeting, but withdrew it after the company struck a licensing agreement with Sanofi.Sanofi is Novavax’s biggest partner. In the second quarter (Q2), the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> is up by 7% this year but down by about 32% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.

Equity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


Shares of MoonLake Immunotherapeutics (MLTX) rebounded 14% on Tuesday after a near 90% plunge on Monday.MoonLake on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/moonlake-stock-crashes-premarket-after-sonelokimab-phase-3-data/chDMDY2R37p">announced</a> 16-week results from its late-stage VELA-1 and VELA-2 identical trials of Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, Sonelokimab achieved statistical significance for all primary and key secondary endpoints, including a substantial improvement in the disease. However, in VELA-2, the drug failed to achieve statistical significance. Subsequently, on Monday, MLTX closed at $6.25, marking its lowest levels in over three years. The stock is currently trading at $7.41.The mixed data drew several price target cuts. Needham analyst Serge Belanger lowered the firm's price target on MoonLake Immunotherapeutics to $20 from $66 on Tuesday, but maintained a ‘Buy’ rating on the shares. The regulatory path looks uncertain, and MoonLake might need to conduct another late-stage trial in the worst-case scenario, the analyst noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_1_04_46_PM_png_2ebbe1ed61.webp" alt="MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rise further.<stembedurl>https://stocktwits.com/Leoheart/message/630505115</stembedurl>Another noted that, although analysts have cut price targets, several targets remain higher than current trading levels.<stembedurl>https://stocktwits.com/Freeballin02/message/630504990</stembedurl>Guggenheim also lowered the firm's price target on the stock to $20 from $80 and kept a ‘Buy’ rating on the shares. While investors are now focused on the drug’s regulatory path, the firm noted that MoonLake is conducting multiple clinical studies across other indications, including palmoplantar pustulosis, psoriatic arthritis, and axial spondyloarthritis. These together sum up to a multibillion-dollar market, the firm noted.Citi analyst Samantha Semenkow, meanwhile, downgraded MoonLake Immunotherapeutics to ‘Neutral’ from ‘Buy’ with a price target of $5, down from $72, on "significant" regulatory risk for the drug. The analyst also noted that Moonlake is currently facing financing challenges.MLTX stock is down by 89% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q">AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

Shares of Trump Media &amp; Technology Group (DJT), the parent company of Truth Social, fell nearly 7% on Wednesday, after a series of high-profile stock sales by key executives, prompting bearish sentiment among retail investors.According to recent SEC filings, the company’s CFO, Phillip Juhan, sold $1.92 million worth of shares, while CEO Devin Nunes offloaded shares worth $63,210.&nbsp;Other executives who sold shares include COO Andrew Northwall ($78,700), CTO Vladimir Novachki ($177,082) and General Counsel and Secretary Scott Glabe ($92,684).The filings clarify that these sales were conducted to cover withholding payments to taxing authorities, with no cash proceeds received by the executives.&nbsp;However, the optics of top executives selling shares have rattled investors.On Stocktwits, sentiment for DJT has turned ‘extremely bearish’ (13/100) amid high levels of chatter.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DJT_sentiment_and_message_volume_Aug_28_c3c9ff623c.png" alt="DJT sentiment and message volume Aug 28.png">One bearish user (with apparent sarcasm) posted, “$DJT strong support at $0,” while another claimed to have profited $82,000 by shorting the stock.<stembedurl>https://stocktwits.com/theta4life/message/584409755</stembedurl>Additionally, a lock-up period barring former President Donald Trump from selling his shares in the company is nearing its end.&nbsp;According to <a href="https://qz.com/donald-trump-media-stock-holdings-djt-lockup-selloff-1851629076">Quartz</a>, Trump’s stake in DJT is under a six-month lockup period that could end as soon as Sept. 20 — if the stock remains above $12 for any 20 trading days starting Aug. 22. If shares fall below $12, the earliest Trump could sell would be Sept. 25, regardless of the stock’s value.&nbsp;John Rekenthaler, Vice President of Research at Morningstar, reportedly believes DJT is “extremely overvalued” and sees it as a great cash-out opportunity for Trump, who in theory has “well over $2 billion to realize.”DJT’s slide has also been exacerbated by a $16.4 million net loss in Q2 and a 30% drop in revenue.&nbsp; Shares of the company, which have been extremely volatile due to news events involving Trump, have lost more than 65% of their value since going public via a SPAC merger in March.<stembedurl>https://stocktwits.com/RonSwanson1/message/584401019</stembedurl>Trump is set to debate Vice President Kamala Harris live on Sept. 10 in Philadelphia. With DJT stock near record lows and a potential Trump stock sale on the horizon, analysts like Rekenthaler warn that a political defeat could push the stock “to zero.”Read Next: <a href="https://stocktwits.com/news/markets/equity/anf-stock-falls-after-q2-results/c7w7XRoR2P">Abercrombie &amp; Fitch Stock Sinks As CEO Points To 'Increasingly Uncertain Environment' — Retail Bulls Aren’t Backing Down</a>&nbsp;&nbsp;&nbsp; &nbsp;

Donald Trump speaking with supporters at a campaign rally at the Phoenix Convention Center in Phoenix, Arizona.

Trump Media & Tech Stock Plummets, Retail Gets ‘Extremely Bearish’ After Key Execs Dump Shares 

A six-month lock-up period barring former President Donald Trump from selling his shares in the company is also nearing its end.

Trump Media &amp; Technology Group (DJT), the parent company of Truth Social, saw its shares fall to a new post-merger low of $21.99 on Tuesday, with retail investor sentiment souring on the stock. &nbsp;According to Stocktwits, sentiment for DJT has turned bearish, falling from ‘neutral’ (36/100) a day earlier.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DJT_sentiment_and_message_volume_Aug_20_14dd9018ba.png" alt="DJT sentiment and message volume Aug 20.png" width="1310" height="316"><figcaption>DJT sentiment and message volume Aug 20</figcaption></figure>The stock hit an intraday low of $22.24 on Monday, slipping nearly 1.3% from its previous low seen in mid-April.This downturn follows several weeks of declining stock prices, exacerbated by a $16.4 million net loss in Q2 and a 30% drop in revenues.Since its Nasdaq debut in March under the ticker DJT, following a merger with Digital World Acquisition Corp., Trump Media's stock has plunged over 61%, with a nearly 36% drop in the past month alone.Shares of the company have been on a volatile ride this year, primarily driven by <a href="https://stocktwits.com/news/markets/equity/trump-media-stock-retail-sentiment-extremely-bearish-after-biden-exits-2024-race/c7rTFviRv">news events</a> involving former President Donald Trump, the company's majority shareholder.Recent setbacks include the stock slipping after Trump returned to Twitter (now X) for a conversation with Elon Musk, the fallout from Trump’s legal troubles and debate performance against President Joe Biden.There was some limited upside movement following <a href="https://stocktwits.com/news/markets/equity/Trump-stocks-surge-after-shooting-but-retail-traders-divided/c7AZ9lnRT">the assassination attempt</a> on Trump in July during a rally near Butler, Pennsylvania.The stock is facing more pressure as the Democratic National Convention convenes in Chicago on Thursday, when Vice President Kamala Harris will formally accept her nomination for the White House race.<stembedurl>https://stocktwits.com/RickeyBobby/message/583493412</stembedurl>Despite Trump Media's rollout of its live TV streaming service, Truth+, retail investors remain pessimistic, with some asking the hard questions.&nbsp;<stembedurl>https://stocktwits.com/Mishka1/message/583489536</stembedurl>As the political landscape heats up, DJT’s stock stands on increasingly shaky ground.See Also:&nbsp;<a href="https://stocktwits.com/news/markets/equity/govx-tnpx-ebs-siga-stocks-face-mixed-signals-on-mpox-news/c7voqTBRTH">Emergent, Geovax, Tonix, Siga: Which Mpox-Linked Stocks Are Retail Investors Most Excited About?</a>

Despite Trump Media's rollout of its live TV streaming service, Truth+, retail investors remain pessimistic. Photo via Rawpixel

Trump Media Stock Declines To Record Post-Merger Low, Retail Sentiment Sours

The stock, closely tied to former President Trump’s actions and legal issues, has plunged over 61% since going public via a SPAC merger this year.

ISCB
iShares Morningstar Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ISCB News

ISCBiShares Morningstar Small-Cap ETF